Member Directory - TB Working Group

Primary tabs

Chair: Susan Swindells

Objectives:

Guide product development and identify knowledge gaps requiring further research and resources for the prevention and treatment of tuberculosis (TB). Our goal is to identify the most promising drug candidates for development as long-acting/extended release (LA/ER) formulations.
Promote the development of LA/ER approaches for TB by building on previous modelling and preclinical work to evaluate novel long-acting formulations of TB drugs.
Develop additional applications to understand if in silico modelling can predict important drug-drug interactions involving LA/ER formulations, a particularly relevant issue for HIV and TB drugs where rifamycins are the source of many complex and significant interactions. Models will also be improved to provide dosing strategies for infants, children, adolescents, and pregnant women.

Interested in joining?
Please submit your request and your CV to Julia Burnett. Acceptance requires a written nomination from a TB Working Group member and majority approval.

Susan Swindells, MBBS sswindells@unmc.edu Susan Swindells is a Professor of Internal Medicine in the Section of Infectious Diseases at the University of Nebraska Medical Center, USA. Conflict of Interest: Receives research grants to her institution from ViiV Healthcare.	Nicole C. Ammerman, PhD nicole.ammerman@jhu.edu Dr. Ammerman is a Researcher at Erasmus University Medical Center Rotterdam, Department of Medical Microbiology & Infectious Diseases; and an adjunct research associate at the Johns Hopkins Center for Tuberculosis Research. Conflict of Interest: Receives research funding from Janssen Pharmaceutica.
Richard Chaisson MD, JHU, Professor of Medicine, Director, Center for TB Research rchaiss@jhmi.edu Richard E. Chaisson, MD, is Professor of Medicine, Epidemiology, and International Health at Johns Hopkins University and Director of the Johns Hopkins Center for TB Research and the Center for AIDS Research. Conflict of Interest: Receives consulting fees from Johnson & Johnson. Spouse has ownership interest in Merck.	Charles W. Flexner, MD flex@jhmi.edu Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP). Conflict of Interest: Dr. Flexner reports receiving consulting income from Gilead Sciences, Merck, ViiV Healthcare, Janssen, and Theratechnologies. He also serves on a scientific advisory board for Navigen Corporation, and serves on a data safety and monitoring board for Advarra. He is a co-inventor on six issued patents related to long-acting drug delivery technology for HIV treatment and prevention.
Elisa H. Ignatius, MD, MSc eignati1@jhmi.edu Elisa H. Ignatius, MD, MSc is an Assistant Professor of Medicine in the Divisions of Infectious Diseases and Clinical Pharmacology at the Johns Hopkins University School of Medicine and Program Director for the Johns Hopkins Center for Nontuberculous Mycobacteria and Bronchiectasis. Conflict of Interest: Has no real or apparent conflicts of interest to report.	Eric Nuermberger, MD enuermb@jhmi.edu Dr. Nuermberger is Professor of Medicine and International Health at Johns Hopkins University. His primary research interest is the experimental chemotherapy of TB. Conflict of Interest: Receives research funding from Janssen and Wintermute.
Andrew Owen, PhD, FSB aowen@liverpool.ac.uk Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology and Director of the Centre of Excellence in Long-acting Therapeutics (CELT; www.liverpool.ac.uk/CELT) at the University of Liverpool. Conflict of Interest: Dr. Owen has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Tandem Nano Ltd., Gilead, Assembly Biosciences.	Charles A. Peloquin, Pharm.D., FCCP peloquin@cop.ufl.edu Dr. Chuck Peloquin received his BS in Pharmacy from the University of Connecticut and his Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science. Conflict of Interest: Has no real or apparent conflicts of interest to report.
Christopher Perrin, Pharm D, MPH Christophe.PERRIN@paris.msf.org Pharmaceutical Advocate to Médecins Sans Frontières on specific dossiers, such as access to Tuberculosis medicines. Conflict of Interest: Has no real or apparent conflicts of interest to report.	Manuele Piccolis, PhD mpiccolis@medicinespatentpool.org Manuele Piccolis holds a PhD in Life Sciences from the University of Geneva and he has an extensive experience in metabolism. Conflict of Interest: Spouse receives salary support from Lunaphore Tech.
Anthony T. Podany apodany@unmc.edu Dr. Podany is currently an Associate Professor in the department of pharmacy practice at the University of Nebraska Medical Center. Conflict of Interest: Has no real or apparent conflicts of interest to report.	Dr. Molebogeng Rangaka (MBChB, PhD) l.rangaka@ucl.ac.uk Dr. Rangaka is an Associate Professor within the Institute of Global Health, University College London (UCL), United Kingdom. Conflict of Interest: Has no real or apparent conflicts of interest to report.
Bart Remmerie, Chem. Eng BREMMERI@its.jnj.com Bart Remmerie, Chem. Eng., graduated as a bio-engineer and as environmental engineer at Ghent University, Belgium. He started at Janssen (Bioanalysis) in 1994. Conflict of Interest: As a Janssen employee I have a wage and shares from/in the company.	Kimberly Scarsi, PharmD, MS kim.scarsi@unmc.edu Dr. Kimberly Scarsi is a Professor at the University of Nebraska Medical Center’s (UNMC) College of Pharmacy. Conflict of Interest:Receives grant funding from Viiv Healthcare Organon, LLC.